EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors

Wenke Li, Menghui Xu, Mo Cheng, Jing Wei, Lin Zhu, Yu Deng, Fukun Guo, Feng Bi, Ming Liu iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71065 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Wenke Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastric Cancer Center/Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital, Sichuan University, Sichuan Province Science and Technology Support Program, Sichuan Provincial Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy combined with chemotherapy has become the standard treatment for HER2‐negative gastric cancer (GC), but its clinical benefits remain limited, with a median progression‐free survival (mPFS) of 6–8 months and median overall survival (mOS) of 15–18 months. These outcomes are particularly poor in patients with CPS < 1. The marked heterogeneity of GC, along with primary and secondary resistance, presents significant clinical challenges and underscores the urgent need for novel therapeutic strategies. Recent Advances To address these limitations, several combination therapies are being explored. Anti‐VEGF therapy combined with immune checkpoint inhibitors (ICIs) has shown synergistic effects by enhancing immune cell infiltration and reducing tumor‐mediated immunosuppression, thereby improving response rates and survival. Radiotherapy combined with ICIs also holds promise, with low‐dose radiation remodeling the tumor microenvironment and high‐dose radiation inducing immunogenic cell death. Other potential combinations include PD‐1/PD‐L1 inhibitors paired with targeted therapies against HER2, FGFR2, DKK1, PARP, LSD1, HDAC, and other emerging targets. Novel approaches such as hyperbaric oxygen therapy, oncolytic viruses, metabolic modulators, and fecal microbiota transplantation are also under investigation to further enhance immune responses.

Conclusion

These multimodal strategies represent a promising shift toward personalized, mechanism‐driven immunotherapy sensitization. By targeting diverse pathways to overcome immune resistance, they aim to reshape the tumor microenvironment, restore immune responsiveness, and improve outcomes in GC. While many remain in early‐stage development, accumulating evidence supports their potential. Future research should prioritize optimizing combination regimens, clarifying resistance mechanisms, and identifying predictive biomarkers through multi‐omics and artificial intelligence to enable more precise, individualized immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsImmune Checkpoint InhibitorsImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansTumor MicroenvironmentCombined Modality TherapyDrug Resistance, Neoplasm

Stichwörter der Autor:innen

PD‐1/PD‐L1 inhibitorsgastric cancerimmunotherapyimmunotherapy sensitization

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Gastric Cancer Center/Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • School of Basic Medical Sciences Chengdu University, Chengdu, Sichuan, China.
  • Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Abdominal Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Ming Liu

Förderung

  • West China Hospital, Sichuan University
  • Sichuan Province Science and Technology Support Program
  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Li, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025). Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors. Cancer Medicine. https://doi.org/10.1002/cam4.71065

Vancouver

Li W, Xu M, Cheng M, Wei J, Zhu L, Deng Y, et al. Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors. Cancer Medicine. 2025. doi:10.1002/cam4.71065

BibTeX
@article{Li2025,
  author = {Li, Wenke and Xu, Menghui and Cheng, Mo and Wei, Jing and Zhu, Lin and Deng, Yu and Guo, Fukun and Bi, Feng and Liu, Ming},
  title = {Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71065}
}
Kostenlos starten →